NCT01904318View on ClinicalTrials.gov

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

January 31, 2014

Conditions
Healthy
Interventions
DRUG

IDP-73152 mesylate 40 mg

IDP-73152 mesylate 40 mg single dose administration

DRUG

IDP-73152 mesylate 80 mg

IDP-73152 mesylate 80 mg single dose administration

DRUG

IDP-73152 mesylate 160 mg

IDP-73152 mesylate 160 mg single dose administration

DRUG

IDP-73152 mesylate 320 mg

IDP-73152 mesylate 320 mg single dose administration

DRUG

IDP-73152 mesylate 640 mg

IDP-73152 mesylate 640 mg single dose administration

DRUG

IDP-73152 mesylate 1280 mg

IDP-73152 mesylate 1280 mg single dose administration

DRUG

Placebo

Placebo single dose administration

Trial Locations (1)

110-744

Seoul National University Hospital, Jongno-gu

Sponsors
All Listed Sponsors
lead

IlDong Pharmaceutical Co Ltd

INDUSTRY

NCT01904318 - A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer | Biotech Hunter | Biotech Hunter